

WHO-Recommended Composition of

INFLUENZA VIRUS VACCINES

for use in the 2023 - 2024 Northern Hemisphere Influenza Season^{1,2}

The World Health Organization (WHO) recommends influenza vaccine strains for use in the northern and southern hemisphere influenza seasons annually.^{1,2}

Influenza Strain Changes^{1,2}

	2023	2023-2024
	Southern Hemisphere ²	Northern Hemisphere ¹
A/Victoria/2570/2019	A/H1N1	A/Sydney/5/2021
A/Darwin/9/2021	A/H3N2	A/Darwin/9/2021
B/Austria/1359417/2021	B/Victoria lineage	B/Austria/1359417/2021
B/Phuket/3073/2013	B/Yamagata lineage	B/Phuket/3073/2013



The First Quadrivalent Influenza Vaccine Indicated for Maternal Immunisation and Passive Protection of Newborns Up To 6 Months of Age^{#5}

The First Quadrivalent Influenza Vaccine Indicated for Maternal Immunisation.⁶ Provide Passive Protection of Newborns Up To 6 Months of Age^{^6}

01

Statistically significant data from an RCT demonstrated **protection against cardiovascular disease** outcomes across geographies and seasons.⁴

02

The first influenza vaccine used in Malaysia and Singapore for **passive protection of infants up to 6 months of age following vaccination of pregnant women.**^{5,6††}

03

Demonstrated efficacy and **reduction of flu-related complications** in children 6 to 35 months old.^{3,6}

04

Well tolerated with a proven safety record and more than 2 billion doses of Vaxigrip/VaxigripTetra[®] distributed worldwide.^{3,7}

05

Protection beyond flu is the new bar for Sanofi influenza vaccines.⁴

How would you rate the content of this email?

Very Poor



Excellent

VaxigripTetra[®] Prescribing Information



 **VAXIGRIPTETRA MY PI**
www.sanofi.com.my/products/vaxigriptetra



 **VAXIGRIPTETRA SG PI**
www.sanofi.com.sg/products/vaxigriptetra

For the full prescribing information, please scan the QR code or visit the link provided.

* Not all infants are protected.

In Malaysia. Accessed as at 19 December 2022, 2022 verified. Influenza Vaccines Registered in Malaysia. Available at Sistem Pendaftaran Produk & Perlesenan <https://quest3plus.bpfk.gov.my/pmo2/index.php>.

^ In Singapore. Accessed as at 19 December 2022, 2022 verified. Influenza Vaccines Registered in Singapore. Available at Singapore Health Science Authority <https://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProduct.do?action=load>.

References:

1. World Health Organization. Recommendations announced for influenza vaccine composition for the 2022-2023 northern hemisphere influenza season. Available at <https://www.who.int/news/item/25-02-2022-recommendations-announced-for-influenza-vaccine-composition-for-the-2022-2023-northern-hemisphere-influenza-season>. Accessed on 9 December 2022.
2. World Health Organization. New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere. Available at <https://www.who.int/news/item/23-09-2022-new-recommendations-for-the-composition-of-influenza-vaccines-in-2023-for-the-southern-hemisphere>. Accessed on 19 December 2022.
3. VaxigripTetra[®] Influenza Vaccine [Summary of Product Characteristics]. Data on file. Sanofi Pasteur Inc. 4. Fröberg O, Götberg M, Erlinge L, et al. Influenza vaccination after myocardial infarction: A randomized, double-blind, placebo-controlled, multicenter trial. *Circulation*. 2021;144(18):1476-1484. doi:10.1161/CIRCULATIONAHA.121.057042.
5. Omer SB, Clark DR, Madhi SA, et al. Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: A pooled analysis of three randomised controlled trials. *Lancet Respir Med*. 2020;8:597-608. doi:10.1016/S2213-2600(19)30479-5.
6. Pepin S, Samson SI, Alvarez FP, et al. Impact of a quadrivalent inactivated influenza vaccine on influenza associated complications and health care use in children aged 6 to 35 months. *Vaccine*. 2019;37(13):1885-1888. doi:10.1016/j.vaccine.2019.01.059.
7. Sanofi. Periodic Benefit Risk Evaluation Report. 4 May, 2020. Data on file.
8. Sesay S, et al. *Hum Vaccin Immunother*. 2018;14(3):596-608.

For Malaysia and Singapore healthcare professionals only



sanofi-aventis (Malaysia) Sdn. Bhd. (334110-P)
Unit TB-18-1, Level 18, Tower B, Plaza 33, No.1 Jalan Kemajuan,
Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan.
Tel: +603-7651 0800 Fax: +603-7651 0801/0802
www.sanofi.com.my

sanofi-aventis Singapore Pte. Ltd.
38 Beach Road #18-11 South Beach Tower Singapore 189767
Tel: +65-6226 3836 (Gen) Fax: +65-6535 5836
www.sanofi.com.sg

© 2023 Sanofi. All rights reserved.
MAT-MY-2300518-1.0-09/23